TY  - JOUR
AU  - Bajić, Vladan
AU  - Sudar-Milovanović, Emina
AU  - Potparević, Biljana
AU  - Živković, Lada
AU  - Miliccivc, Zorka
AU  - Stanimirović, Julijana
AU  - Bogdanović, Nikola
AU  - Isenović, Esma
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2591
AB  - Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder, and represents the most common form of dementia. The number of people affected by AD is estimated to be doubled by the year of 2050, and more than 100 million people worldwide will be affected by this disease. Still, there is no reliable diagnostic test which would indicate pre-symptomatic conditions or an increased risk of developing AD. The only drugs approved by the FDA belong to the cholinesterase inhibitors (ChEI) group, such as donepezil, rivastigmine, galantamine and memantine that belongs to a class of drugs named receptor NMDA antagonists. Most mainstream pharmacotherapeutic approaches act by slowing the progression of the condition rather than to treat or prevent the cause of AD. In this review we are presenting literature data from recent research related to new avenues in the classical approach to prevention and treatment of AD.
PB  - Bentham Science Publ Ltd, Sharjah
T2  - Current Pharmaceutical Analysis
T1  - Treatment of Alzheimer's Disease: Classical Therapeutic Approach
VL  - 12
IS  - 2
SP  - 82
EP  - 90
DO  - 10.2174/1573412911666150611184740
ER  - 

@article{
author = "Bajić, Vladan and Sudar-Milovanović, Emina and Potparević, Biljana and Živković, Lada and Miliccivc, Zorka and Stanimirović, Julijana and Bogdanović, Nikola and Isenović, Esma",
year = "2016",
abstract = "Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder, and represents the most common form of dementia. The number of people affected by AD is estimated to be doubled by the year of 2050, and more than 100 million people worldwide will be affected by this disease. Still, there is no reliable diagnostic test which would indicate pre-symptomatic conditions or an increased risk of developing AD. The only drugs approved by the FDA belong to the cholinesterase inhibitors (ChEI) group, such as donepezil, rivastigmine, galantamine and memantine that belongs to a class of drugs named receptor NMDA antagonists. Most mainstream pharmacotherapeutic approaches act by slowing the progression of the condition rather than to treat or prevent the cause of AD. In this review we are presenting literature data from recent research related to new avenues in the classical approach to prevention and treatment of AD.",
publisher = "Bentham Science Publ Ltd, Sharjah",
journal = "Current Pharmaceutical Analysis",
title = "Treatment of Alzheimer's Disease: Classical Therapeutic Approach",
volume = "12",
number = "2",
pages = "82-90",
doi = "10.2174/1573412911666150611184740"
}

Bajić, V., Sudar-Milovanović, E., Potparević, B., Živković, L., Miliccivc, Z., Stanimirović, J., Bogdanović, N.,& Isenović, E.. (2016). Treatment of Alzheimer's Disease: Classical Therapeutic Approach. in Current Pharmaceutical Analysis
Bentham Science Publ Ltd, Sharjah., 12(2), 82-90.
https://doi.org/10.2174/1573412911666150611184740

Bajić V, Sudar-Milovanović E, Potparević B, Živković L, Miliccivc Z, Stanimirović J, Bogdanović N, Isenović E. Treatment of Alzheimer's Disease: Classical Therapeutic Approach. in Current Pharmaceutical Analysis. 2016;12(2):82-90.
doi:10.2174/1573412911666150611184740 .

Bajić, Vladan, Sudar-Milovanović, Emina, Potparević, Biljana, Živković, Lada, Miliccivc, Zorka, Stanimirović, Julijana, Bogdanović, Nikola, Isenović, Esma, "Treatment of Alzheimer's Disease: Classical Therapeutic Approach" in Current Pharmaceutical Analysis, 12, no. 2 (2016):82-90,
https://doi.org/10.2174/1573412911666150611184740 . .